強
強気
強気 · 25%SLN
$2.94
シナリオ価格
$8.680
-0.622 (-7.17%)終値時点
Loading chart…
- 高値
- 9.220
- 始値
- 9.100
- 出来高加重平均価格
- 8.85
- 出来高
- 1.13M
- 時価総額
- 886.54M
- 安値
- 8.660
- 売買代金
- 10.01M
- EV/EBITDA（TTM）
- -6.52
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
AI分析 of Silence Therapeutics PLC (SLN)
中立Silence Therapeutics PLC is not a good buy right now due to its current price of $8.68 being significantly below analyst targets and a very low RSI of 24.913 indicating oversold conditions. The company has shown a substantial year-to-date change of +41.14%, but recent performance has been poor with a 5-day change of -11.97%. The main risk is the high net loss of $12.2 million reported in Q2 2026, which raises concerns about financial stability.
バリュエーション指標
Silence Therapeutics PLC（SLN）の現在の予想PERは0.00で、5年平均は-14.69です。
Alphio AI による SLN の価格シナリオ
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。
SLN を保有するクジラ
イベントタイムライン
ニュース
8.508-14NewsfilterSilence Therapeutics Closes $201.3 Million Public Offering
- 8.508-12Newsfilter
Silence Therapeutics Prices Public Offering at $13.50 per ADS
8.508-11NASDAQ.COMSilence Therapeutics Proposes $150 Million Public Offering
8.508-11NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Positive Catalysts
- 7.508-10Newsfilter
Socket Mobile Partners with 3Eye Technologies to Expand Distribution
SLN のよくある質問 — Alphio AI が回答
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Silence Therapeutics PLC is not a good buy right now due to its current price of $8.68 being significantly below analyst targets and a very low RSI of 24.913 indicating oversold conditions. The company has shown a substantial year-to-date change of +41.14%, but recent performance has been poor with a 5-day change of -11.97%. The main risk is the high net loss of $12.2 million reported in Q2 2026, which raises concerns about financial stability.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。